Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Lord

Showing results (11-20 of 222) with videos related to

Pageof 23
Sort By:
Nature Reviews. Clinical Oncology|February 14, 2020
First-line PARP inhibition in ovarian cancer - standard of care for all?Susana N Banerjee, Christopher J Lord
Critical Reviews in Oncology/Hematology|December 10, 2016
PARP inhibitor combination therapyAmy Dréan, Christopher J Lord, Alan Ashworth
Cell Cycle (Georgetown, Tex.)|July 8, 2008
Dissecting resistance to endocrine therapy in breast cancerChristopher J Lord, Elizabeth Iorns, Alan Ashworth
The Biochemical Journal|November 4, 2008
Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitizationElizabeth Iorns, Christopher J Lord, Alan Ashworth
Methods in Molecular Biology (Clifton, N.J.)|January 19, 2018
Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line PanelsJames Campbell, Colm J Ryan, Christopher J Lord
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Targeting the double-strand DNA break repair pathway as a therapeutic strategyChristopher J Lord, Michelle D Garrett, Alan Ashworth
Cancer Cell|September 10, 2014
DAISY: picking synthetic lethals from cancer genomesColm J Ryan, Christopher J Lord, Alan Ashworth
Elife|May 29, 2020
Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactionsChristopher J Lord, Niall Quinn, Colm J Ryan
Current Opinion in Genetics & Development|March 18, 2008
DNA repair deficiency as a therapeutic target in cancerSarah A Martin, Christopher J Lord, Alan Ashworth
Nature Reviews. Drug Discovery|December 1, 2012
Tankyrase-targeted therapeutics: expanding opportunities in the PARP familyJenna L Riffell, Christopher J Lord, Alan Ashworth
Pageof 23

Showing results (11-20 of 222) with videos related to

Sort By:
Pageof 23
Nature Reviews. Clinical Oncology|February 14, 2020
First-line PARP inhibition in ovarian cancer - standard of care for all?Susana N Banerjee, Christopher J Lord
Critical Reviews in Oncology/Hematology|December 10, 2016
PARP inhibitor combination therapyAmy Dréan, Christopher J Lord, Alan Ashworth
Cell Cycle (Georgetown, Tex.)|July 8, 2008
Dissecting resistance to endocrine therapy in breast cancerChristopher J Lord, Elizabeth Iorns, Alan Ashworth
The Biochemical Journal|November 4, 2008
Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitizationElizabeth Iorns, Christopher J Lord, Alan Ashworth
Methods in Molecular Biology (Clifton, N.J.)|January 19, 2018
Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line PanelsJames Campbell, Colm J Ryan, Christopher J Lord
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Targeting the double-strand DNA break repair pathway as a therapeutic strategyChristopher J Lord, Michelle D Garrett, Alan Ashworth
Cancer Cell|September 10, 2014
DAISY: picking synthetic lethals from cancer genomesColm J Ryan, Christopher J Lord, Alan Ashworth
Elife|May 29, 2020
Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactionsChristopher J Lord, Niall Quinn, Colm J Ryan
Current Opinion in Genetics & Development|March 18, 2008
DNA repair deficiency as a therapeutic target in cancerSarah A Martin, Christopher J Lord, Alan Ashworth
Nature Reviews. Drug Discovery|December 1, 2012
Tankyrase-targeted therapeutics: expanding opportunities in the PARP familyJenna L Riffell, Christopher J Lord, Alan Ashworth
Pageof 23